Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Rochlitz

Showing results (41-50 of 44) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 44 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 3, 2010
Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06)C Rochlitz, T Ruhstaller, S Lerch, et al.
ESMO Open|January 8, 2022
Targeting immunoliposomes to EGFR-positive glioblastomaB Kasenda, D König, M Manni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 22, 2016
Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99O Pagani, D Klingbiel, T Ruhstaller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2001
Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II studyM Schuler, R Herrmann, J L De Greve, et al.
Pageof 5

Showing results (41-50 of 44) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 44 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 3, 2010
Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06)C Rochlitz, T Ruhstaller, S Lerch, et al.
ESMO Open|January 8, 2022
Targeting immunoliposomes to EGFR-positive glioblastomaB Kasenda, D König, M Manni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 22, 2016
Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99O Pagani, D Klingbiel, T Ruhstaller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2001
Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II studyM Schuler, R Herrmann, J L De Greve, et al.
Pageof 5